| Original language | English |
|---|---|
| Pages (from-to) | 606-608 |
| Number of pages | 3 |
| Journal | The Lancet Oncology |
| Volume | 20 |
| Issue number | 5 |
| DOIs |
|
| State | Published - May 2019 |
| Externally published | Yes |
Bibliographical note
Funding Information:DM has received honoraria for lectures from Amgen, Bayer, HalioDx, Merck Serono, Merck Sharpe & Dohme (MSD), Roche, Sanofi, and Servier; honoraria for participation in advisory boards from Agios, Bayer, HalioDx, MSD, Roche, Servier, Shire, and Halio Dx; and travel support from Amgen, Bayer, Merck Serono, MSD, Roche, Sanofi, and Servier. JE reports grants from BTG, and personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Ipsen, and Novartis. He is the coordinating investigator of PRODIGE 12, an adjuvant chemotherapy study in biliary tract cancer, discussed in this comment and the related article.
Funding
DM has received honoraria for lectures from Amgen, Bayer, HalioDx, Merck Serono, Merck Sharpe & Dohme (MSD), Roche, Sanofi, and Servier; honoraria for participation in advisory boards from Agios, Bayer, HalioDx, MSD, Roche, Servier, Shire, and Halio Dx; and travel support from Amgen, Bayer, Merck Serono, MSD, Roche, Sanofi, and Servier. JE reports grants from BTG, and personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Ipsen, and Novartis. He is the coordinating investigator of PRODIGE 12, an adjuvant chemotherapy study in biliary tract cancer, discussed in this comment and the related article.
| Funders | Funder number |
|---|---|
| Novartis |
